EUVIMEDEUVIMED entdecken
Crossref

Improving Pharmacokinetics of PSMA/GRPR-Targeting Radiolabeled Heterodimer through Enhanced Albumin Binding

Shohei Tsuchihashi, Kazuma Nakashima iD, Hiroyuki Watanabe iD, Masahiro Ono iD

Molecular Pharmaceutics · 03.08.2026 · 23 (8) · 4166-4180

DOI: 10.1021/acs.molpharmaceut.6c00209 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 14.07.2026. Verfasst von Shohei Tsuchihashi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, 46-29 Yoshida Shimoadachi-cho, Sakyo-Ku, Ky…. Hauptthemen laut MEDLINE: Glutamate Carboxypeptidase II, Prostatic Neoplasms, Receptors, Bombesin, Albumins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Radiolabeled heterodimers targeting prostate-specific membrane antigen (PSMA) and gastrin-releasing peptide receptor (GRPR) have been extensively investigated to overcome heterogeneous target expression in prostate cancer. However, low tumor retention and high kidney uptake remain major challenges. In this study, we designed and synthesized a novel albumin binder (ALB)-modified PSMA/GRPR-targeting heterodimer, PADA, to improve tumor retention and tumor-to-kidney ratios. [111In]In-PADA exhibited marked binding ability to albumin, PSMA, and GRPR in vitro. In biodistribution studies, the tumor retention of [111In]In-PADA was improved by the introduction of ALB in both PSMA-positive and GRPR-positive tumor-bearing mice. Overall, the tumor AUC values and tumor-to-kidney AUC value ratios of [111In]In-PADA were higher than those of a control agent without an ALB moiety in both model mice. In single-photon emission computed tomography (SPECT) imaging studies, [111In]In-PADA could be used to successfully visualize both PSMA-positive and GRPR-positive tumors and exhibited enhanced tumor-to-kidney contrast due to the introduction of ALB. These results suggest that [111In]In-PADA exhibits favorable pharmacokinetics as a PSMA/GRPR-targeting heterodimer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glutamate Carboxypeptidase IIProstatic NeoplasmsReceptors, BombesinAlbuminsAntigens, SurfaceRadiopharmaceuticalsAnimalsMaleMiceTissue DistributionHumansIndium RadioisotopesTomography, Emission-Computed, Single-PhotonCell Line, TumorMice, Nude

Stichwörter der Autor:innen

albumin bindergastrin-releasing peptide receptorheterodimerprostate cancerprostate-specific membrane antigentumor retention

Substanzen

Glutamate Carboxypeptidase IIReceptors, BombesinIndium RadioisotopesAlbuminsFOLH1 protein, humanAntigens, SurfaceRadiopharmaceuticals

Autor:innen und Institutionen

  • Department of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, 46-29 Yoshida Shimoadachi-cho, Sakyo-Ku, Kyoto606-8501, Japan.

ORCID-Profile: Kazuma Nakashima, Hiroyuki Watanabe, Masahiro Ono

Förderung

  • Japan Agency for Medical Research and Development
  • Japan Society for the Promotion of Science

Zitieren

APA

Tsuchihashi, S., Nakashima, K., Watanabe, H., & Ono, M. (2026). Improving Pharmacokinetics of PSMA/GRPR-Targeting Radiolabeled Heterodimer through Enhanced Albumin Binding. Molecular Pharmaceutics, 23(8), 4166-4180. https://doi.org/10.1021/acs.molpharmaceut.6c00209

Vancouver

Tsuchihashi S, Nakashima K, Watanabe H, Ono M. Improving Pharmacokinetics of PSMA/GRPR-Targeting Radiolabeled Heterodimer through Enhanced Albumin Binding. Molecular Pharmaceutics. 2026;23(8):4166-4180. doi:10.1021/acs.molpharmaceut.6c00209

BibTeX
@article{Tsuchihashi2026,
  author = {Tsuchihashi, Shohei and Nakashima, Kazuma and Watanabe, Hiroyuki and Ono, Masahiro},
  title = {Improving Pharmacokinetics of PSMA/GRPR-Targeting Radiolabeled Heterodimer through Enhanced Albumin Binding},
  journal = {Molecular Pharmaceutics},
  year = {2026},
  volume = {23},
  number = {8},
  pages = {4166--4180},
  doi = {10.1021/acs.molpharmaceut.6c00209}
}
Kostenlos starten →